Search Results

There are 6432 results for: content related to: Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia

  1. You have free access to this content
    Effect of Switch to the Highest Dose of Rosuvastatin Versus Add-on-Statin Fenofibrate Versus Add-on-Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia

    Cardiovascular Therapeutics

    Volume 32, Issue 4, August 2014, Pages: 139–146, Anastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, Alexandros Tselepis and Moses Elisaf

    Article first published online : 9 JUL 2014, DOI: 10.1111/1755-5922.12072

  2. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

    European Journal of Clinical Investigation

    Volume 43, Issue 7, July 2013, Pages: 698–707, Anastazia Kei, Evangelos Liberopoulos, Kostantinos Tellis, Manfredi Rizzo, Moses Elisaf and Alexandros Tselepis

    Article first published online : 20 APR 2013, DOI: 10.1111/eci.12095

  3. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations

    International Journal of Evidence-Based Healthcare

    Volume 10, Issue 3, September 2012, Pages: 181–190, Ian Hamilton-Craig, Karam Maximilien Kostner, Stan Woodhouse and David Colquhoun

    Article first published online : 23 AUG 2012, DOI: 10.1111/j.1744-1609.2012.00275.x

  4. Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

    The Journal of Clinical Pharmacology

    Volume 44, Issue 9, September 2004, Pages: 1054–1062, Dr Arthur J. Bergman, Dr Gail Murphy, Ms Joanne Burke, Dr Jamie J. Zhao, Mr Robert Valesky, Ms Lida Liu, Dr Kenneth C. Lasseter, Dr Weili He, Dr Thomayant Prueksaritanont, Mr Yue Qiu, Dr Alan Hartford, Dr Jose M. Vega and Dr John F. Paolini

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270004268044

  5. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: The eutectic microstructure

    Journal of Pharmaceutical Sciences

    Volume 92, Issue 3, March 2003, Pages: 505–515, Devalina Law, Weili Wang, Eric A. Schmitt, Yihong Qiu, Steven L. Krill and James J. Fort

    Article first published online : 12 DEC 2002, DOI: 10.1002/jps.10324

  6. Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans

    The Journal of Clinical Pharmacology

    Volume 50, Issue 8, August 2010, Pages: 914–921, Dr Tong Zhu, Dr Jean-Claude Ansquer, Dr Maureen T. Kelly, Dr Darryl J. Sleep and Dr Rajendra S. Pradhan

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009354995

  7. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies

    Cardiovascular Therapeutics

    Volume 33, Issue 6, December 2015, Pages: 329–337, Christelle Foucher, Patrick Aubonnet, Petr Reichert, Mario Berli, Axel Schaeffer, Cesar Gonzalo Calvo Vargas, Anna Lochocka, Dmitry Belenky, Hans-Friedrich Koch and for the Cholib study Investigators

    Article first published online : 2 NOV 2015, DOI: 10.1111/1755-5922.12148

  8. You have free access to this content
    Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor

    British Journal of Pharmacology

    Volume 155, Issue 4, October 2008, Pages: 596–605, Z Huang, X Zhou, A C Nicholson, A M Gotto Jr, D P Hajjar and J Han

    Article first published online : 29 JAN 2009, DOI: 10.1038/bjp.2008.331

  9. You have free access to this content
    Fenofibrate and the kidney: an overview

    European Journal of Clinical Investigation

    Volume 43, Issue 5, May 2013, Pages: 522–531, Michael S. Kostapanos, Matilda Florentin and Moses S. Elisaf

    Article first published online : 11 MAR 2013, DOI: 10.1111/eci.12068

  10. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate

    Journal of Pharmacy and Pharmacology

    Jennifer B. Dressman, Elisabeth Herbert, Alena Wieber, Gudrun Birk, Christoph Saal and Dieter Lubda

    Article first published online : 10 AUG 2015, DOI: 10.1111/jphp.12465

  11. You have free access to this content
    Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate–activated protein kinase–dependent induction of orphan nuclear receptor small heterodimer partner

    Hepatology

    Volume 50, Issue 3, September 2009, Pages: 880–892, Dipanjan Chanda, Chul Ho Lee, Yong-Hoon Kim, Jung-Ran Noh, Don-Kyu Kim, Ji-Hoon Park, Jung Hwan Hwang, Mi-Ran Lee, Kyeong-Hoon Jeong, In-Kyu Lee, Gi Ryang Kweon, Minho Shong, Goo-Taeg Oh, John Y. L. Chiang and Hueng-Sik Choi

    Article first published online : 27 APR 2009, DOI: 10.1002/hep.23049

  12. Biomolecular Chemistry of Isopropyl Fibrates

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 4, April 2012, Pages: 1555–1569, Ganesaratnam K. Balendiran, Niharika Rath, Amanda Kotheimer, Chad Miller, Matthias Zeller and Nigam P. Rath

    Article first published online : 13 JAN 2012, DOI: 10.1002/jps.23040

  13. Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

    The Journal of Clinical Pharmacology

    Volume 51, Issue 3, March 2011, Pages: 378–388, Dr Lloyd R. Whitfield, Dr Anthony R. Porcari, Ms Christine Alvey, Dr Robert Abel, Mr William Bullen and Dr Daniel Hartman

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010366446

  14. Individual and Combined Effects of Peroxisome Proliferator-Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 504–513, Dr J. A. Wagner, P. J. Larson, S. Weiss, J. L. Miller, Dr T. W. Doebber, M. S. Wu, Dr D. E. Moller and Dr K. M. Gottesdiener

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270004273136

  15. You have free access to this content
    Activation of PPARα inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines

    International Journal of Cancer

    Volume 123, Issue 5, 1 September 2008, Pages: 1015–1024, Katarzyna Urbanska, Paola Pannizzo, Maja Grabacka, Sidney Croul, Luis Del Valle, Kamel Khalili and Krzysztof Reiss

    Article first published online : 10 JUN 2008, DOI: 10.1002/ijc.23588

  16. Choice of Nonionic Surfactant Used to Formulate Type IIIA Self-Emulsifying Drug Delivery Systems and the Physicochemical Properties of the Drug Have a Pronounced Influence on the Degree of Drug Supersaturation that Develops During In Vitro Digestion

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 4, April 2014, Pages: 1050–1063, Ravi Devraj, Hywel D. Williams, Dallas B. Warren, Christopher J. H. Porter and Colin W. Pouton

    Article first published online : 27 JAN 2014, DOI: 10.1002/jps.23856

  17. AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-κB pathway

    Environmental Toxicology

    Shih-Chang Tsai, Ming-Hsui Tsai, Chang-Fang Chiu, Chi-Cheng Lu, Sheng-Chu Kuo, Nai-Wen Chang and Jai-Sing Yang

    Article first published online : 24 DEC 2014, DOI: 10.1002/tox.22097

  18. You have free access to this content
    Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

    Journal of Internal Medicine

    Volume 251, Issue 6, June 2002, Pages: 490–499, J.-P. Després, I. Lemieux, H. Salomon and D. Delaval

    Article first published online : 22 MAY 2002, DOI: 10.1046/j.1365-2796.2002.00988.x

  19. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 9, September 2014, Pages: 780–792, A. Sahebkar and G. F. Watts

    Article first published online : 11 MAR 2014, DOI: 10.1111/dom.12277

  20. The peroxisome proliferator-activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung

    Fundamental & Clinical Pharmacology

    Volume 26, Issue 3, June 2012, Pages: 340–346, Julien Becker, Carine Delayre-Orthez, Nelly Frossard and Françoise Pons

    Article first published online : 11 MAR 2011, DOI: 10.1111/j.1472-8206.2011.00935.x